Novo CEO blasts ‘mass compounding’ of GLP-1 drugs as safety battle escalates Novo Nordisk’s CEO says compounded GLP-1 knockoffs sourced from overseas ingredients could endanger patients and undermine FDA oversight as legal battle escalates. Orignial Source: https://www.foxbusiness.com/media/novo-ceo-blasts-mass-compounding-glp-1-drugs-safety-battle-escalates Previous article: Amazon Pharmacy to expand same-day prescription delivery to 4,500 US cities Prev Next article: Expert credits Trump tax certainty for economic confidence, Americans returning to workforce Next
